Intratumoral plasma cells are required for immune checkpoint blockade therapy in de novo MPNSTs

Using an immunocompetent mouse model of de novo malignant peripheral nerve sheath tumors (MPNSTs), we found that plasma cells are required for successful anti-PD-L1 therapy and extended survival.

In order to uncover the role of plasma cells in this response, we performed scRNA-seq of de novo MPNSTs within wild-type controls versus plasma cell-deficient AID-/-; µS-/- mice following CDK4/6-MEK inhibition. These results support our hypothesis that response to anti-PD-L1 is influenced by plasma cell infiltration into MPNSTs following CDK4/6-MEK inhibition.